Lupin's shares increased by 21.51% over the past year. However, year-to-date (YTD), the stock has decreased by 14.21%. Over ...
The Financial Express on MSN6mon
Health Canada gives nod to Lupin’s biosimilar to treat infection in cancer patientsThis product will be marketed under the brand name Armlupeg and manufactured at Lupin’s Biotech facility in Pune, India.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback